Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Amgen Terminates $540 Million Deal with Advaxis

Shares of Advaxis plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated their collaboration on an immuno-oncology program.

Read More »

J&J shares nosedive on report company knew of asbestos in baby powder

Shares of Johnson & Johnson tumbled 12 percent after Reuters reported that the pharma major knew for decades that cancer-causing asbestos lurked in the company’s Baby Powder.

Read More »

Why Type One Diabetes Patients Need Closed Loop Insulin Systems

For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.

Read More »

Moderna Therapeutics Sets Record for Biggest Biotech IPO

The long-awaited and massively hyped initial public offering (IPO) of Moderna Therapeutics hit the market.

Read More »

Top Trends in Digital Health in 2019

2018 was the year of the consumer, and there is no sign of a change any time soon.

Read More »

FDA Approves NIH-Funded Genetic Database, Issues Draft Guidance on NASH

The FDA issued draft guidance for biopharma companies on developing therapies for NASH with liver fibrosis.

Read More »

Medtronic Will Pay $51 Million To Settle DOJ Investigation Against Two Company Acquisitions

Medtronic will pay a total of nearly $51 million to resolve three legal claims against Covidien Plc and ev3 Inc., two companies that are now part of the Ireland-based medtech company. Medtronic itself had no role in the wrongdoings that resulted in the multi-million fines.

Read More »

Johnson & Johnson’s multiple myeloma drug reduces risk of death in late-stage study

Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.

Read More »

RedHill’s antibiotic succeeds in late-stage study

RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

Read More »

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom